Status:
COMPLETED
Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance
Lead Sponsor:
Novartis
Conditions:
Prediabetic State
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering post-meal blood glucose levels in people with pre-diabetes who ...
Eligibility Criteria
Inclusion
- Blood glucose criteria must be met
- Body mass index (BMI) in the range 23-45
Exclusion
- Diagnosis of diabetes
- Serious cardiovascular events within the past 6 months
- Use of insulin or any oral antidiabetic agent
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
171 Patients enrolled
Trial Details
Trial ID
NCT00237250
Start Date
October 1 2005
End Date
July 1 2006
Last Update
May 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936